High performance liquid chromatographic method for the analysis of omeprazole and 5-hydroxyomeprazole in human plasmaTATA, P. N. V; BRAMER, S. L.Analytical letters. 1999, Vol 32, Num 11, pp 2285-2295, issn 0003-2719Article

Effect of omeprazole on the metabolism of cilostazolSURI, A; BRAMER, S. L.Clinical pharmacokinetics. 1999, Vol 37, pp 53-59, issn 0312-5963, SUP2Article

Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazolBRAMER, S. L; SURI, A.Clinical pharmacokinetics. 1999, Vol 37, pp 41-51, issn 0312-5963, SUP2Article

Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and womenSURI, A; FORBES, W. P; BRAMER, S. L et al.Journal of clinical pharmacology. 1998, Vol 38, Num 2, pp 144-150, issn 0091-2700Article

Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarinMALLIKAARJUN, S; BRAMER, S. L.Clinical pharmacokinetics. 1999, Vol 37, pp 79-86, issn 0312-5963, SUP2Article

Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazolBRAMER, S. L; FORBES, W. P.Clinical pharmacokinetics. 1999, Vol 37, pp 25-32, issn 0312-5963, SUP2Article

Biologic activity of 5'-deoxy-5-fluorouridine by rectal administrationBRAMER, S. L; GUNNARSSON, L. C; LAI SIM AU, J et al.Pharmaceutical research. 1989, Vol 6, Num 4, pp 318-322, issn 0724-8741Article

Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in ratsLAI-SIM AU, J; WIENTJES, M. G; BRAMER, S. L et al.Cancer chemotherapy and pharmacology. 1988, Vol 22, Num 1, pp 5-10, issn 0344-5704Article

The preparation of soft gelatin capsules for a radioactive tracer studyTESCONI, M. S; BRAMER, S. L; YALKOWSKY, S. H et al.Pharmaceutical development and technology. 1999, Vol 4, Num 4, pp 507-513, issn 1083-7450Article

Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectumBRAMER, S. L; WIENTJES, M. G; AU, J. L.-S et al.Pharmaceutical research. 1993, Vol 10, Num 5, pp 763-770, issn 0724-8741Article

Gastrointestinal and hepatic first-pass elimination of 2',3'-dideoxyinosine in ratsBRAMER, S. L; AU, J. L.-S; WIENTJES, M. G et al.The Journal of pharmacology and experimental therapeutics. 1993, Vol 265, Num 2, pp 731-738, issn 0022-3565Article

Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatographyFU, C. J; TATA, P. N. V; OKADA, K et al.Journal of chromatography. B, Biomedical sciences and applications. 1999, Vol 728, Num 2, pp 251-262, issn 1387-2273Article

Interaction potential and tolerability of the coadministration of cilostazol and aspirinMALLIKAARJUN, S; FORBES, W. P; BRAMER, S. L et al.Clinical pharmacokinetics. 1999, Vol 37, pp 87-93, issn 0312-5963, SUP2Article

Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial diseaseBRAMER, S. L; FORBES, W. P; MALLIKAARJUN, S et al.Clinical pharmacokinetics. 1999, Vol 37, pp 1-11, issn 0312-5963, SUP2Article

Effect of age and gender on the pharmacokinetics of grepafloxacinEFTHYMIOPOULOS, C; BRAMER, S. L; MAROLI, A et al.Clinical pharmacokinetics. 1997, Vol 33, pp 9-17, issn 0312-5963, SUP1Article

Effect of food and gastric pH on the bioavailability of grepafloxacinEFTHYMIOPOULOS, C; BRAMER, S. L; MAROLI, A et al.Clinical pharmacokinetics. 1997, Vol 33, pp 18-24, issn 0312-5963, SUP1Article

Effect of multiple cilostazol doses on single dose Lovastatin pharmacokinetics in healthy volunteersBRAMER, S. L; BRISSON, J; COREY, A. E et al.Clinical pharmacokinetics. 1999, Vol 37, pp 69-77, issn 0312-5963, SUP2Article

The quantitative determination of cilostazol and its four metabolites in human liver microsomal incubation mixtures by high-performance liquid chromatographyTATA, P. N. V; FU, C.-H. J; BROWDER, N. J et al.Journal of pharmaceutical and biomedical analysis. 1998, Vol 18, Num 3, pp 441-451, issn 0731-7085Article

Theophylline and warfarin interaction studies with grepafloxacinEFTHYMIOPOULOS, C; BRAMER, S. L; MAROLI, A et al.Clinical pharmacokinetics. 1997, Vol 33, pp 39-46, issn 0312-5963, SUP1Article

Grepafloxacin pharmacokinetics in individuals with hepatic dysfunctionEFTHYMIOPOULOS, C; BRAMER, S. L; MAROLI, A et al.Clinical pharmacokinetics. 1997, Vol 33, pp 25-31, issn 0312-5963, SUP1Article